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Abstract
Several recent genome-wide association studies have identiﬁed genetic variants associated with breast cancer.
However, how much these genetic variants may help advance breast cancer risk prediction based on other clinical
features, like mammographic ﬁndings, is unknown. We conducted a retrospective case-control study, collecting
mammographic ﬁndings and high-frequency/low-penetrance genetic variants from an existing personalized medicine
data repository. A Bayesian network was developed using Tree Augmented Naive Bayes (TAN) by training on the
mammographic ﬁndings, with and without the 22 genetic variants collected. We analyzed the predictive performance
using the area under the ROC curve, and found that the genetic variants signiﬁcantly improved breast cancer risk
prediction on mammograms. We also identiﬁed the interaction effect between the genetic variants and collected
mammographic ﬁndings in an attempt to link genotype to mammographic phenotype to better understand disease
patterns, mechanisms, and/or natural history.
1 Introduction
Large multi-relational databases containing variables that confer disease risk are increasingly available, providing the
opportunity for informatics tools to better stratify individuals for appropriate healthcare decisions and explore disease
mechanism and behavior. Coincident to this, policy-makers have recommended that interventions, like breast cancer
screening with mammography, be increasingly based on individualized risk and shared decision-making1,2. Targeting
at risk individuals for intervention after mammographic screening has the potential to decrease recommendations for
breast biopsy in women most likely to have an unnecessary procedure for benign ﬁndings. Recent large-scale genome-
wide association studies have identiﬁed 22 susceptibility loci associated with breast cancer (Table 1). In addition,
there is a long history of development and codiﬁcation of features observed by radiologists on mammography that
also predict a woman’s risk of breast cancer. However, genetics and mammography abnormality ﬁndings have not
yet been used together to predict risk. Furthermore, the opportunity to use this data to interpret genotype/phenotype
association, explain family aggregation of breast cancer, and shed light on disease mechanism or natural history is just
becoming possible.
There have been several attempts to incorporate these genetic variants into the Gail model3 which is a standard clinical
breast cancer risk model including the number of ﬁrst-degree relatives with a diagnosis of breast cancer, age at menar-
che, age at ﬁrst live birth and the number of previous breast biopsies. Seven associated SNPs, when added to the Gail
model, increase the area under the receiver operating characteristic (ROC) curve from 0.607 to 0.6324,5. When ten
associated SNPs are added to the Gail model, the area under the ROC curve of the risk model increases from 0.580 to
0.618 on another dataset6. However, the Gail model does not include any mammography features which are clinically
used by radiologists. Therefore, it is still unknown how much these genetic variants improve breast cancer diagnosis
and clinical decision-making after an abnormal mammogram.
The ﬁrst purpose of this study is to examine the impact of genetic information on improving breast cancer risk pre-
diction on mammograms. We incorporate genetic polymorphisms with the descriptors that radiologists observe on
mammograms while making medical decisions, the American College of Radiology Breast Imaging Reporting and
Data System (BI-RADS)7, version 4, including the shape and the margin of masses, the shape and the distribution
of microcalciﬁcations, background breast density and other associated ﬁndings as deﬁned by this standard lexicon inTable 1: SNPs evaluated for altered risk of breast cancer.
SNP ID CHR ALLELE OR IN GAIL (2008,2009) IN WACHOLDER ET AL (2010)
RS11249433
9 1 C 0.99 YES
RS4666451
10 2 A 0.83
RS13387042
11,9 2 G 0.68 YES YES
RS1045485
12 2 C 0.86 YES YES
RS17468277
13 2 T 0.86
RS4973768
14 3 T 0.99
RS10941679
15,9 5 G 1.39 PROXY OF RS7716600
RS981782
10 5 G 0.82
RS30099
10 5 T 1.07
RS889312
10 5 C 1.20 YES YES
RS2180341
16 6 G 1.10
RS2046210
17 6 T 0.91
RS13281615
10 8 G 1.26 YES YES
RS2981582
10,18,16,15,9 10 T 1.18 YES YES
RS3817198
10,9 11 C 1.16 YES YES
RS2107425
10 11 T 1.20
RS6220
19,20 12 G 1.24
RS999737
9 14 T 0.98 YES
RS3803662
10,11,9 16 T 1.14 YES YES
RS8051542
10 16 T 1.29
RS12443621
10 16 G 0.93
RS6504950
14 17 A 0.81
Chr: the chromosome the SNP locates.
Allele: the minor allele.
OR: the allelic odds-ratio in the Marshﬁeld Clinic population.
breast imaging. We also include a small number of predictive variables not included in BI-RADS currently. Speciﬁ-
cally, we employ these mammographic ﬁndings (49 mammography descriptors) and the 22 genetic variants associated
with breast cancer in 404 case subjects and 399 control subjects from a personalized medicine data repository at the
Marshﬁeld Clinic. We train a Bayesian network using Tree Augmented Naive Bayes (TAN)8 on the mammographic
ﬁndings, with and without the 22 genetic variants.
The second purpose of this study is to identify the interaction effect between the genetic variants and the mammo-
graphic ﬁndings toward risk prediction, in order to understand the genotype/phenotype relationships that may eluci-
date disease patterns that may not be otherwise evident in this complex multi-relational data. The interaction between
the genetic variants and the mammographic ﬁndings also sheds light on how the associated SNPs function to in-
crease or decrease the risk of breast cancer. Speciﬁcally, we calculate the conditional mutual information between the
mammography features and the genetic variants given the class variable on the entire dataset.
2 Materials and Methods
2.1 Data
[Subjects] The Personalized Medicine Research Project21 at the Marshﬁeld Clinic was used as the sampling frame
to identify breast cancer cases and controls. The project was reviewed and approved by the Marshﬁeld Clinic IRB.
Subjects were selected using clinical data from Marshﬁeld Clinic Cancer Registry and Data Warehouse. We employed
a retrospective case-control design. Women with a plasma sample available, a mammogram, and a breast biopsy
within 12 months after the mammogram were included in the study. Cases were deﬁned as women having a conﬁrmed
diagnosis of breast cancer obtained from the institutional cancer registry. Controls were conﬁrmed through the elec-
tronic medical records (and absence from the cancer registry) as never having had a breast cancer diagnosis. In ourMass
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Figure 1: Mammography features adopted from the American College of Radiology (BI-RADS lexicon).
case cohort, we included both invasive breast cancer (ductal and lobular) as well as ductal carcinoma in situ. In order
to construct case and control cohorts that were similar in age distribution, we employed an age matching strategy.
Speciﬁcally, we selected a control whose age was within ﬁve years of the age of each case. Of note, we decided to
focus on high-frequency/low-penetrance genes that affect breast cancer risk as opposed to low frequency genes with
high penetrance (BRCA1 and BRCA2) or intermediate penetrance (CHEK-2). High-frequency/low-penetrance SNPs
generally have frequencies for the rarest allele of > 25% as opposed to the low-frequency, high-penetrance mappings
with population frequencies of < 1%. We excluded individuals who had a known high penetrance genetic mutation.
[Genetic Variants] Our study included 22 genetic variants which have been identiﬁed by recent large-scale genome-
wide association studies. Table 1 summarizes detailed information about the 22 SNPs, including the IDs, the original
publications associating them with breast cancer, their chromosomes, the minor alleles and the allelic odds-ratios of the
SNPs in the Marshﬁeld Clinic population. The seven SNPs used in Gail study4,5 were also included in our study. Nine
of the ten SNPs used in Wacholder et al study6 were included in our study, and the remaining SNP rs7716600 from
that study had a proxy rs10941679 in our study. We observed that each SNP only confers a slight increase or decrease
in the risk of breast cancer, in accordance with prior literature. Among the 22 associated SNPs, 11 are associated with
an increased risk of breast cancer (OR>1.0) and 11 are associated with a decreased risk of breast cancer (OR<1.0).
When we built the models with the genetic variants, we coded each genetic variant as whether the subject carries the
minor allele, rather than the speciﬁc genotype the subject carries.
[Mammography Features] The American College of Radiology developed the BI-RADS lexicon7 to homogenize
mammographic ﬁndings and recommendations. The BI-RADS lexicon consists of a number of mammography de-
scriptors, including the characteristics of masses and microcalciﬁcations, background breast density and other asso-
ciated ﬁndings, which can be organized in a hierarchy as shown in Figure 1. Datasets containing mammography
descriptors have been used to build several successful breast cancer risk models and classiﬁers22,23. Mammography
data was originally recorded as free text reports in the Marshﬁeld database, and thus it was difﬁcult to directly access
the information contained therein. We used a parser to extract mammography features from the text reports; the parser
has been shown to outperform manual extraction24,25. After extraction, every mammography feature takes the value
“present” or “not present” except that the variable mass size is discretized into three values, “not present”, “small” and“large”, depending whether there is a reported mass size and whether any dimension of the reported mass size is larger
than 30mm.
Each mammogram also has a BI-RADS category assigned by the radiologist who read the mammogram. The BI-
RADS category indicates the radiologist’s opinion of the absence or presence of breast cancer. In our study, the
BI-RADS assessment category can take values, with an order of increasing probability of malignancy, of 1, 2, 3,
0, 4a, 4, 4b, 4c and 5. We used the BI-RADS assessment category as the predictions from the radiologists. Our
experiment only included diagnostic mammograms, and all the screening mammograms were excluded. Since most of
the subjects have multiple diagnostic mammograms in the electronic medical records, we selected one mammogram
for each subject as follows, to mimic the scenario of the most important doctor visit before diagnosis. For cases, we
selected the mammograms within one year prior to diagnosis. For controls, we selected the mammograms within one
year prior to biopsy. If there were still multiple mammograms left for each subject, we selected the mammogram
with a more suspicious BI-RADS category, with subsequent tiebreakers being, in order, recency and the number of
extracted mammography features.
2.2 Model
We build breast cancer risk models using Bayesian networks, which have been used with mammography data to im-
prove breast cancer diagnosis and clinical decision-making for physicians involved in breast cancer care26,27. Bayesian
networks are directed acyclic graphs that allow efﬁcient and effective representation of the joint probability distribution
over a set of random variables. Each vertex in the graph represents a random variable, and edges represent conditional
independence between the variables. In this paper, we use a special type of Bayesian network model, namely TAN8,
which is an effective, provably efﬁcient supervised learning model which captures the strongest pairwise interactions
between the features in a compact way. Training a TAN model starts with learning a Naive Bayes model with the
case/control output being the class variable and all the other variables being the features. Naive Bayes assumes that all
features are conditionally independent of one another given the class28. Because this assumption may be too strong,
the TAN learning algorithm next builds a maximum spanning tree over the feature variables with the weight between
two variables being the conditional mutual information between two features conditional on the class variable. Even-
tually the parameters in the model, namely the conditional probability tables, are estimated from the data. In our
experiments, we use the TAN implementation in WEKA29.
In total, we construct three TAN models built on different sets of features. The ﬁrst model is built purely on the 49
mammography features, namely the breast imaging model. The second model is based purely on the 22 associated
SNPs, namely the genetic model. The third model is built on the 49 mammography features and the 22 associated SNPs
together, namely the combined model. We treat the BI-RADS category scores from the radiologists as the predictions
from the radiologists, namely the baseline clinical assessment. We construct ROC curves for each model, and use the
area under the curve (AUC) as a measure of performance of the models. We also provide the precision-recall (PR)
curves for the models. We evaluate the models in the 10-fold cross-validation fashion. The 404 cases and 399 controls
are randomly divided in 10 folds. In each round of the 10-fold cross-validation, we select one fold as the testing data
and the remaining nine folds as the training data, so that each fold is used exactly once for testing.
We further evaluate the interaction between the SNPs and the mammography features toward predicting the class label
(case or control). Speciﬁcally, we calculate the conditional mutual information (CMI) between the 22 SNPs and the
49 mammography features given the class label. We also calculate the 95% conﬁdence intervals for the CMI between
each SNP and each mammography feature via bootstrapping. We randomly draw samples with replacement from the
404 cases and the 399 controls, and calculate the conditional mutual information. We bootstrap for 1;000 times and
calculate the corresponding 1;000 CMI values. We sort the 1;000 CMI values from the smallest to the largest, and
report the 26-th smallest value and the 26-th largest value as the boundaries of the 95% conﬁdence interval.
3 Results
We succeeded in identifying 404 cases for which we could match a mammogram within a year prior to a biopsy. We
then identiﬁed age-matched controls; however at the end of data collection and veriﬁcation, 5 of the controls wereTable 2: The distribution of age at mammogram and family breast cancer history in the cases and the controls.
AGE CASES CONTROLS
< 50 96 67
 50;< 65 141 171
 65 167 161
FAMILY HISTORY CASES CONTROLS
YES 178 134
NO 215 251
UNKNOWN 11 14
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Figure 2: The vertical averaged ROC curves and PR curves for the genetic model, the breast imaging model, the
combined model and the baseline clinical assessment.
conﬁrmed to have breast cancer leaving us with 399 controls for which we could match a mammogram within a year
prior to a biopsy. Among the 404 cases, there are 401 Caucasian cases, two Asian Hmong cases and one case whose
race information is unknown. Among the 399 controls, there are 395 Caucasian controls, three Caucasian/American
Indian controls, and one Caucasian/Asian Hmong control. We summarize the distribution of the ages and family breast
cancer history of the cases and the controls in Marshﬁeld population in Table 2. There are more young people (age
< 50) in the case group than in the control group, and the proportion of elderly people (age  65) is roughly the same
in the case group and in the control group. For the family history of breast cancer, we observe a considerable larger
proportion of people with family history in the case group than in the control group, which demonstrates the family
aggregation of breast cancer.
The ROC curves and the PR curves for the baseline clinical assessment, the breast imaging model, the genetic model
and the combined model are provided in Figure 2, respectively. For each type of model we vertically average30 its
ROC curves from the ten replications of the 10-fold cross-validation to obtain the ﬁnal curve; we do likewise for the
PR curves. The area under the ROC curves for the genetic model, the breast imaging model and the combined model
are 0.603, 0.693 and 0.731, respectively. The ROC curve of the combined model almost completely dominates the
ROC curve of the breast imaging model, which suggests that adding the 22 genetic variants can help to improve the
breast cancer risk prediction based on mammographic ﬁndings. We perform a two-sided paired t-test on the area under
the ten ROC curves of the breast imaging model and the area under the ten ROC curves of the combined model from
the 10-fold cross-validation, and the difference between them is signiﬁcant with a P-value 0.021. From the PR curves,
it is also observed that the combined model dominates the breast imaging model and the baseline clinical assessment
at the high recall region (> 0:8) in which we would like to operate, and therefore which we want to optimize.
For each SNP, we summarize the mammography feature with the highest conditional mutual information, the condi-S
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.Table 4: The contingency tables for SNPs rs4666451, rs1045485, rs2180341 and rs2981582 and their interacting
mammography features.
CASES CONTROLS
RS1045485 CARRY C NOT CARRY C CARRY C NOT CARRY C
PLEOMORPHIC CALCIFICATION PRESENT 3 57 13 57
PLEOMORPHIC CALCIFICATION NOT PRESENT 83 261 82 247
RS2180341 CARRY G NOT CARRY G CARRY G NOT CARRY G
DYSTROPHIC CALCIFICATION PRESENT 0 10 3 6
DYSTROPHIC CALCIFICATION NOT PRESENT 185 209 168 222
RS2981582 CARRY T NOT CARRY T CARRY T NOT CARRY T
DIFFUSE CALCIFICATION PRESENT 9 2 11 0
DIFFUSE CALCIFICATION NOT PRESENT 251 142 235 153
RS4666451 CARRY A NOT CARRY A CARRY A NOT CARRY A
OVAL MASS PRESENT 0 2 9 0
OVAL MASS NOT PRESENT 245 157 257 133
tional mutual information value and the corresponding 95% conﬁdence intervals in Table 3. Most of the interaction
effect is moderate with small CMI values. There are four noteworthy interaction pairs between the genetic variants and
the mammography features toward breast cancer risk prediction with the conditional mutual information above 0:01.
The four interaction pairs are (1) SNP rs1045485 (rs17468277) andpleomorphic calciﬁcations (CMI=0.0141), (2) SNP
rs2180341 and dystrophic calciﬁcations (CMI=0.0115), (3) SNP rs2981582 and diffuse calciﬁcations (CMI=0.0112)
and (4) SNP rs4666451 and oval masses (CMI=0.0100).
4 Discussion
We found that adding the 22 genetic polymorphisms to the 49 radiologist-reported mammographic ﬁndings statis-
tically signiﬁcantly increased the accuracy (as measured by AUC-ROC) of our Bayesian network model, despite a
small sample size. In our preliminary exploration of genotype/phenotype relationships, we identiﬁed 4 potentially
noteworthy interacting pairs between the genetic variants and the mammographic ﬁndings. These observations im-
ply that radiologists may beneﬁt from the availability of patient genotype information when they are making their
interpretations of mammogram results.
Statistical models by Gail4,5 and Wacholder et al6 added genetic risk factors to epidemiologic risk factors and found
modest improvements in predictive performance. All of these studies used all or a portion of the carefully validated
and widely disseminated Gail model (a logistic regression model) as the baseline model. The variables included in the
most recent analysis6 were the number of ﬁrst-degree relatives with a diagnosis of breast cancer, age at menarche, age
at ﬁrst live birth, study entry year, and the number of previous breast biopsies. These investigators added 10 common
genetic variants associated with breast cancer in 5;590 case subjects and 5;998 controls. They found that the AUC
of the non-genetic model was 0.580, whereas the model with genetic component added (10 SNPs) revealed an AUC
of 0.618. Importantly, no model to date has included mammography features describing breast ﬁndings. It is not
surprising that our discriminative abilities are superior to prior models because we are using highly predictive features
from mammography including abnormality descriptors and breast density, which to date, have not been included in
previous models. Therefore, we are encouraged by our promising preliminary results.
With the contingency tables in Table 4, we further explore the four interacting pairs from a clinical standpoint:
 SNP rs1045485 (rs17468277) and pleomorphic calciﬁcations: The protective minor allele C of SNP rs1045485
was associated with a reduced risk of breast cancer in the genome-wide association study12 with an allelic
odds-ratio 0.88, and we observe that the allelic odds-ratio in the Marshﬁeld Clinic population is 0.86. Two
earlier studies31,32 found that polymorphisms in CASP8 (rs1045485 and rs1045485/rs17468277) appeared to
be speciﬁcally associated with a reduced risk of ductal tumors. Generally, pleomorphic calciﬁcations are amalignant descriptor on mammograms indicating ductal carcinoma in situ. We observe 60 cases and 70 controls
with pleomorphic calciﬁcations in our data. However, 13 out of the 70 controls carry the minor allele C of
rs1045485 whereas only 3 out of the 60 cases carry the minor allele. Therefore, when the person does not carry
C at rs1045485 and develops pleomorphic calciﬁcation, it is more likely the abnormality is malignant.
 SNP rs2180341 and dystrophic calciﬁcations: The risky minor allele G of SNP rs2180341 was identiﬁed to be
associated with an increased risk of breast cancer in the genome-wide association study16 with an allelic odds-
ratio 1.41, and we observe that the allelic odds-ratio in the Marshﬁeld Clinic population is 1.10. Our odds-ratio
estimate is consistent with a recent study33 in which the allelic odds-ratio is estimated to be 1.07 in the Cypriot
population. Dystrophic calciﬁcation is generally a benign descriptor on mammograms although we observe 10
cases and 9 controls with dystrophic calciﬁcation in our data. However, none of the cases carry the minor allele
G of SNP rs2180341 whereas 3 of the 9 controls carry the minor allele G. Therefore, dystrophic calciﬁcations
continue to be a benign feature even if a woman carries the minor allele G of SNP rs2180341.
 SNP rs2981582 and diffuse calciﬁcations: SNP rs2981582 lies in intron 2 of FGFR2 (ﬁbroblast growth factor
receptor 2), and its risky allele T has been identiﬁed to be associated with an increased risk of breast cancer
in several studies10,18,16,15,9 with an allelic odds-ratio 1.2610, and we observe that the allelic odds-ratio in the
Marshﬁeld Clinic population is 1.18. Diffuse calciﬁcations on mammograms are generally benign. In our
dataset, we observe in total 22 people (11 cases and 11 controls) with diffuse calciﬁcations. However, 20 of the
22 people carry the minor allele T of SNP rs2981582, and the 2 people not carrying allele T are both cases.
 SNPrs4666451andovalmasses: TheprotectiveminoralleleAofSNPrs4666451wasassociatedwithareduced
risk of breast cancer in a previous genome-wide association study10 with an allelic odds-ratio 0.97, and we
observe the allelic odds-ratio in the Marshﬁeld Clinic population is 0.83. Among the 404 breast cancer cases
and 399 controls, there are only 11 subjects (2 cases and 9 controls) whose mammograms exhibit oval masses.
However, all the controls carry the minor allele A of rs4666451, whereas neither of two cases carry the minor
allele A. Oval masses are generally benign indicators, and we can further strengthen this belief if we know the
person also carries minor allele A of SNP rs4666451.
There are some unavoidable limitations in our study, due to the inherent difﬁculty of collecting a rich multi-relational
dataset. First, the sample size is small compared with large-scale genome-wide association studies10,18,16,15,9. How-
ever, other studies do not include mammography features or abnormality data4,5,6. Second, all the mammogram reports
in the original database are in free text, rather than structured reports. Although we extract the features with an ac-
curate parser24,25, this extra step introduces noise, and in particular may miss important features for certain subjects.
Third, for each SNP we pick the mammography feature with highest CMI value among the 49 mammography features.
Although we evaluate the 95% conﬁdence intervals for the CMI’s, the selected mammography features may appear
promising by chance. This risk of false positive association generated by this CMI analysis is further exacerbated by
small sample size. However, exploring genotype/phenotype relationships is only a secondary goal of this project and
we approach this analysis with caution, realizing we need more data and reﬁned methodologies to validate our ﬁndings
and to eliminate selection bias or the multiple comparison effect.
5 Conclusion
Our study represents the ﬁrst exploration of breast cancer risk prediction using genetic polymorphisms along with
mammography features. The fact that genetic risk factors improve risk prediction to a statistically signiﬁcant degree
raises the possibility that stratiﬁcation based on these risk factors may provide an opportunity to personalize care.
In addition, we plan to further develop the concept of exploring genotype/phenotype relationships to shed light on
disease processes that may, in the future, improve diagnosis and treatment. Though we fully realize the necessity of
increasing our sample size to validate these promising preliminary results, we are cautiously optimistic of the power
of multi-relational databases, like the one we have constructed, both to test risk prediction hypotheses and engage in
data-mining that would not otherwise be possible.Acknowledgements
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